At the time of trial initiation in 2015, limited clinical data were available regarding the potential to select patients for treatment with PI3K/mTOR/AKT inhibitors based on pathway alterations/mutations in tumor tissue at baseline. The gene discussed is AKT1; the disease is neoplasm.